Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02102204 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
A Phase 3 study of Hyperparathyroidism, Secondary, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 902
- Enrollment target
- 20
- Study locations
NCT02102204 is a Phase 3 study of Hyperparathyroidism, Secondary that has completed, run by Amgen. The registered enrollment target is 902 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT02102204, a Phase 3 study of Hyperparathyroidism, Secondary, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 902 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, single-arm, extension study to characterize the long-term safety and tolerability of etelcalcetide in the treatment of Secondary Hyperparathyroidism (SHPT) in adults with Chronic Kidney Disease (CKD) on hemodialysis.
Conditions Studied
Interventions
- DRUG Etelcalcetide
Study Locations (20)
California
- Research Site - Alhambra
- Research Site - Azusa
- Research Site - Bakersfield
- Research Site - Cudahy
- Research Site - Granada Hills
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Riverside
- Research Site - Simi Valley
- Research Site - Vacaville
- Research Site - Whittier
Florida
- Research Site - Miami
- Research Site - Ocala
- Research Site - Pembroke Pines
- Research Site - Tampa
Colorado
- Research Site - Aurora
- Research Site - Westminster
Alabama
- Research Site - Birmingham
Connecticut
- Research Site - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02102204
The ClinicalTrials.gov registry entry for NCT02102204 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperparathyroidism, Secondary appearing as the primary indexed condition, and to 1 intervention - of which Etelcalcetide is the first listed.
NCT02102204 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02102204 about?
NCT02102204 is a clinical study titled "Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis". This is a multicenter, single-arm, extension study to characterize the long-term safety and tolerability of etelcalcetide in the treatment of Secondary Hyperparathyroidism (SHPT) in adults with Chronic Kidney Disease (CKD) on hemodialysis.
What is the current status of trial NCT02102204?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 902 participants. The study started on 2014-03-25. Estimated completion is 2017-06-26.
What conditions does trial NCT02102204 study?
This clinical trial studies the following conditions: Hyperparathyroidism, Secondary.
What interventions are being tested in trial NCT02102204?
The interventions under investigation include: Etelcalcetide (DRUG).
Who is sponsoring clinical trial NCT02102204?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02102204 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperparathyroidism, Secondary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.